MARS an improved de novo peptide candidate selection method for non-canonical antigen target discovery in cancer
peer-reviewed · Nature Communications · 2024
| Date | 2024-01-22 |
| Type | peer-reviewed |
| Venue | Nature Communications |
| Publisher | Nature Communications |
| Contribution | downstream-application |
| DOI | 10.1038/s41467-023-44460-z |
| Citations (OpenAlex) | 20 |
| Venue 2-year citedness | 15.88 |
Preprint version: MARS: Improved De Novo Peptide Candidate Selection for Non-Canonical Antigen Target Discovery in Cancer (2022-08-04, Research Square)
Abstract
Understanding the nature and extent of non-canonical human leukocyte antigen (HLA) presentation in tumour cells is a priority for target antigen discovery for the development of next generation immunotherapies in cancer. We here employ a de novo mass spectrometric sequencing approach with a refined, MHC-centric analysis strategy to detect non-canonical MHC-associated peptides specific to cancer without any prior knowledge of the target sequence from genomic or RNA sequencing data. Our strategy integrates MHC binding rank, Average local confidence scores, and peptide Retention time prediction for improved de novo candidate Selection; culminating in the machine learning model MARS. We benchmark our model on a large synthetic peptide library dataset and reanalysis of a published dataset of high-quality non-canonical MHC-associated peptide identifications in human cancer. We achieve almost 2-fold improvement for high quality spectral assignments in comparison to de novo sequencing alone with an estimated accuracy of above 85.7% when integrated with a stepwise peptide sequence mapping strategy. Finally, we utilize MARS to detect and validate lncRNA-derived peptides in human cervical tumour resections, demonstrating its suitability to discover novel, immunogenic, non-canonical peptide sequences in primary tumour tissue.
Methods and tools
- MARS: Non-canonical antigen selection
Cites (10)
- Personalized deep learning of individual immunopeptidomes to identify neoantigens for cancer vaccines (2020) semanticscholar
- pNovo 3: precise de novo peptide sequencing using a learning-to-rank framework (2019) both
- Prosit: proteome-wide prediction of peptide tandem mass spectra by deep learning (2019) both
- Personalized deep learning of individual immunopeptidomes to identify neoantigens for cancer vaccines (2019) crossref
- Deep learning enables de novo peptide sequencing from data-independent-acquisition mass spectrometry (2018) both
- De novo peptide sequencing by deep learning (2017) both
- Evaluating de novo sequencing in proteomics: already an accurate alternative to database-driven peptide identification? (2017) both
- PEAKS DB: De Novo Sequencing Assisted Database Search for Sensitive and Accurate Peptide Identification (2012) crossref
- PEAKS: powerful software for peptide de novo sequencing by tandem mass spectrometry (2003) crossref
- Error-Tolerant Identification of Peptides in Sequence Databases by Peptide Sequence Tags (1994) both